Cargando…

Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib

Early acquisition of sorafenib resistance is responsible for the dismal prognosis of advanced hepatocarcinoma (HCC). Autophagy, a catabolic process involved in liver homeostasis, has been associated with chemosensitivity modulation. Forkhead box O3 (FOXO3) is a transcription factor linked to HCC pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fondevila, Flavia, Méndez-Blanco, Carolina, Fernández-Palanca, Paula, Payo-Serafín, Tania, van Pelt, Jos, Verslype, Chris, González-Gallego, Javier, Mauriz, José L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583804/ https://www.ncbi.nlm.nih.gov/pubmed/34769197 http://dx.doi.org/10.3390/ijms222111770

Ejemplares similares

Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells
por: Méndez-Blanco, Carolina, et al.
Publicado: (2019)

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
por: Méndez-Blanco, Carolina, et al.
Publicado: (2018)

Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis
por: Fondevila, Flavia, et al.
Publicado: (2021)

Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
por: Fondevila, Flavia, et al.
Publicado: (2019)

Antitumor Effects of Quercetin in Hepatocarcinoma In Vitro and In Vivo Models: A Systematic Review
por: Fernández-Palanca, Paula, et al.
Publicado: (2019)

Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy
por: Prieto-Domínguez, Néstor, et al.
Publicado: (2017)

Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies
por: Fernández-Palanca, Paula, et al.
Publicado: (2022)

Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis
por: Méndez-Blanco, Carolina, et al.
Publicado: (2021)

Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
por: Fernández-Palanca, Paula, et al.
Publicado: (2022)

Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
por: Fernández-Palanca, Paula, et al.
Publicado: (2023)

Melatonin as an Antitumor Agent against Liver Cancer: An Updated Systematic Review
por: Fernández-Palanca, Paula, et al.
Publicado: (2021)

Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
por: López-Grueso, María José, et al.
Publicado: (2019)

A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma
por: Salcher, Stefan, et al.
Publicado: (2019)

Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy
por: Sun, Yixiao, et al.
Publicado: (2022)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity
por: Yoshioka, Naoki, et al.
Publicado: (2019)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells
por: Adjibade, Pauline, et al.
Publicado: (2015)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Modulation of Autophagy by Sorafenib: Effects on Treatment Response
por: Prieto-Domínguez, Nestor, et al.
Publicado: (2016)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Potential Use of Chemoprotectants against the Toxic Effects of Cyanotoxins: A Review
por: Guzmán-Guillén, Remedios, et al.
Publicado: (2017)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

The Diversity of Chemoprotective Glucosinolates in Moringaceae (Moringa spp.)
por: Fahey, Jed W., et al.
Publicado: (2018)

Chemoprotective and chemosensitizing effects of apigenin on cancer therapy
por: Nozhat, Zahra, et al.
Publicado: (2021)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Regulation of Multidrug Resistance Proteins by Genistein in a Hepatocarcinoma Cell Line: Impact on Sorafenib Cytotoxicity
por: Rigalli, Juan Pablo, et al.
Publicado: (2015)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2018)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib
por: Nix, Ryan, et al.
Publicado: (2019)

Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
por: Hong, Young Mi, et al.
Publicado: (2021)

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
por: Oronsky, Bryan, et al.
Publicado: (2018)

Amygdalin as a chemoprotective agent in co-treatment with cisplatin
por: Christodoulou, Panayiota, et al.
Publicado: (2022)

Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment
por: Borgia, Francesco, et al.
Publicado: (2017)

Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib
por: Colombatto, Piero, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5akc29pnqb0bn8nrv0ptua8747